Stock PTIX PROTAGENIC THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Protagenic Therapeutics, Inc.

Equities

PTIX

US74365N2027

Market Closed - Nasdaq
Other stock markets
 21:30:00 28/06/2024 BST 		5-day change 1st Jan Change
0.905 USD +0.56% Intraday chart for Protagenic Therapeutics, Inc. -9.50% -8.59%
05-15 Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-01 Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
CI
Protagenic Therapeutics Achieves First Clinical Safety Milestone with Its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
CI
Protagonist Therapeutics, Inc. Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Reverse Split: 1 of 4
FA
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial
CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
Protagenic Therapeutics, Inc. has completed an IPO in the amount of $13.197 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PTIX Stock
  4. News Protagenic Therapeutics, Inc.
  5. Highlights